In the last trading session, 1.19 million TG Therapeutics Inc. (NASDAQ:TGTX) shares changed hands as the company’s beta touched 2.10. With the company’s per share price at $29.80 changed hands at -$0.28 or -0.93% during last session, the market valuation stood at $4.35B. TGTX’s last price was a discount, traded about -90.4% off its 52-week high of $56.74. The share price had its 52-week low at $21.06, which suggests the last value was 29.33% up since then. When we look at TG Therapeutics Inc.’s average trading volume, we note the 10-day average is 1.23 million shares, with the 3-month average coming to 1.48 million.
Analysts gave the TG Therapeutics Inc. (TGTX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.90. If we narrow down to specifics, the data shows that 0 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 1 recommended TGTX as a Hold, 7 felt it is a Buy and 0 rated the stock as Underweight. TG Therapeutics Inc.’s EPS for the current quarter is expected to be -$0.56.
TG Therapeutics Inc. (NASDAQ:TGTX) trade information
Instantly TGTX was in red as seen at the end of in last trading. With action -0.96%, the performance over the past five days has been red. The drop to weekly highs of 30.94 on Tuesday, 09/14/21 subtracted -0.93% to the stock’s daily price. The company’s shares are showing year-to-date downside of -42.71%, with the 5-day performance at -0.96% in the red. However, in the 30-day time frame, TG Therapeutics Inc. (NASDAQ:TGTX) is 30.76% up. Looking at the short shares, we see there were 11.43 million shares sold at short interest cover period of 9.1 days.
The consensus price target for the stock as assigned by Wall Street analysts is $59.88, meaning bulls need an upside of 50.23% from its current market value. According to analyst projections, TGTX’s forecast low is $33.00 with $84.00 as the target high. To hit the forecast high, the stock’s price needs a -181.88% plunge from its current level, while the stock would need to soar -10.74% for it to hit the projected low.
TG Therapeutics Inc. (TGTX) estimates and forecasts
Data shows that the TG Therapeutics Inc. share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -36.73% over the past 6 months, a 2.07% in annual growth rate that is considerably lower than the industry average of 15.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for TG Therapeutics Inc. will rise 23.30%, while the growth in revenue is estimated to hit 21.10% for the next quarter. Year-over-year growth is forecast to reach 9,900.00% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of $2.97 million. 7 analysts are of the opinion that TG Therapeutics Inc.’s revenue for the quarter ending Dec 2021 will be $9.72 million. The company’s revenue for the corresponding quarters a year ago was $38k and $38k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 7,715.80%. The estimates for the next quarter sales put growth at 25,478.90%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -11.90%. The 2021 estimates are for TG Therapeutics Inc. earnings to decrease by -23.80%.
TG Therapeutics Inc. is expected to release its next quarterly earnings report between November 08 and November 12.
TG Therapeutics Inc. (NASDAQ:TGTX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 6.53% of TG Therapeutics Inc. shares while 76.87% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 82.24%. There are 76.87% institutions holding the TG Therapeutics Inc. stock share, with FMR, LLC the top institutional holder. As of Mar 30, 2021, the company held 12.70% of the shares, roughly 17.97 million TGTX shares worth $866.19 million.
Vanguard Group, Inc. (The) holds the second largest percentage of outstanding shares, with 7.86% or 11.12 million shares worth $536.19 million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund. With 3.44 million shares estimated at $165.94 million under it, the former controlled 2.43% of total outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held about 2.10% of the shares, roughly 2.97 million shares worth around $143.05 million.